Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833619 | 1.00 | GAA (0.49) | GAAPKMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6596244 | 0.91 | GAA (0.57) | GAAPKMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6596242 | 0.91 | GAA (0.57) | GAAPKMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28757209 | 0.86 | CCNC (0.45) | MEN1KMT2ASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL28757208 | 0.86 | CCNC (0.45) | MEN1KMT2ASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL4825707 | 0.84 | SMN1; SMN2 (0.46) | GAAPKMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4825715 | 0.84 | SMN1; SMN2 (0.46) | GAAPKMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4831278 | 0.84 | KMT2A (0.43) | GAAPKMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6429798 | 0.83 | MMP1 (0.46) | MEN1KMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL4831264 | 0.80 | EGFR (0.43) | SMN1; SMN2KDM4EPTGER4RAB9AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20050032860-A1 | CBI analogs of CC-1065 and the duocarmycins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
| US-20040002528-A1 | CBI analogs of CC-1065 and the duocarmycins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-01-01 | — | — | US | disclosed |
| US-6548530-B1 | Antitumor drugs incorporate the 1,2,9,9a-tetrahydrocyclopropa(c)benz(e)indol-4-one (CBI) alkylation subunit; cytotoxic activity | THE SCRIPPS RESEARCH INSTITUTE | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | GAA 4645/4885PKM 4622/4885MEN1 3516/4885 |
| US-20040002528-A1 | CBI analogs of CC-1065 and the duocarmycins | DBI, DCK, CCNI | GAA 2484/4885PKM 3231/4885MEN1 2594/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | GAA 4645/4885PKM 4622/4885MEN1 3516/4885 |
| US-20050032860-A1 | CBI analogs of CC-1065 and the duocarmycins | DBI, CCNI, DCK | GAA 2287/4885PKM 3043/4885MEN1 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.